AI imaging software uses deep learning to detect findings (intracranial hemorrhage, large-vessel occlusion, pulmonary embolism, lung nodules), quantify disease burden (LVO, ejection fraction, breast density), or triage worklists. Many AI imaging tools are cleared through 510(k) for triage, detection or quantification. FDA's list of AI-enabled devices shows radiology as the largest category. Predetermined change control plans let some products update models within agreed limits.

Why it matters

Cleared as SaMD; commercial success depends on hospital workflow integration, PACS connectivity, and dedicated reimbursement (NTAP, Category III CPT). Growing Predetermined Change Control Plan (PCCP) adoption for model updates.

Common pitfalls

•A common pitfall is failing to validate the AI algorithm on diverse, representative datasets, leading to biased performance and inaccurate diagnoses in real-world clinical populations.
•Another mistake is neglecting to establish robust post-market surveillance mechanisms to monitor the AI's performance drift and manage updates in a controlled manner.
•Some manufacturers underestimate the regulatory burden associated with modifications to AI models, especially when the changes impact the safety or effectiveness of the device.
•Assuming that a Predetermined Change Control Plan (PCCP) eliminates all regulatory submissions for AI model updates is incorrect; significant changes still require review.
•Not adequately addressing cybersecurity risks, such as data privacy breaches or malicious attacks on the AI model, can lead to patient harm and regulatory non-compliance.

Sources

FDA AI/ML enabled devices list · FDA
AdvaMed - Industry Reports · AdvaMed
MedTech Europe - Facts & Figures · MedTech Europe

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.